SMMT
Summit Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 4 ▲ 3 insiders buy $3.6M at $14.57
- Jun 12 ▲ 2 insiders buy $100.0M at $13.12
- Jul 22 ▲ Summit Therapeutics reported updated overall survival (OS) data from…
- Aug 5 ▲ Summit Therapeutics announced the expansion of its ivonescimab clini…
- Aug 26 ▲ Partner Akeso announced positive topline results from the Phase III…
- Sep 3 ▲ Partner Akeso announced statistically significant overall survival (…
- Sep 9 ▲ Jefferies upgrades
- Sep 14 ▲ Summit Therapeutics announced via 8-K that its partner Akeso present…
- Sep 15 ▲ Summit Therapeutics presented updated overall survival (OS) data fro…
- Sep 29 ▲ Summit Therapeutics entered into a securities purchase agreement wit…
- Nov 4 Summit Therapeutics reported Q3 2026 financial results with no reven…
- Nov 14 FDA decision: PDUFA: SMMT, ivonescimab in EGFR-mutated locally advanced…
- Nov 16 New report: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
3 insiders bought $103.6M at an average $13.17. No open-market sales. Price is 10% below their cost.
- InstitutionsBULLISH
Q2 2026: 34 added (1 new), 13 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $29.0M.
- AnalystsBULLISH
17 of 24 rate it Buy or better.
- Short sellersSTEADY
Short interest +3.3% to 42.26M shares. 9.4 days to cover, ≈5.3% of shares.
- TrendDOWNTREND
27% below its 50-day average. New closing low $11.82 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 1.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $139.0M |
| UBS Group AG | ADD | $76.3M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $65.8M |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | $56.7M |
| Point72 Asset Management, L.P. | DOUBLED | $53.9M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | $34.2M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | $29.0M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | $27.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
24 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Oct 1, 2026 | Barclays MAINTAIN | Equal-Weight |
| Sep 29, 2026 | Citigroup MAINTAIN | Buy |
| Sep 23, 2026 | HC Wainwright & Co. REITERATE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Anand Bhaskar Chief Accounting Officer Oct 8, 2026 | AWARD | 100,000 sh |
DUGGAN ROBERT W Co-Chief Executive Officer Jun 12, 2026 | BUY | $50.0M |
Zanganeh Mahkam Co-Chief Executive Officer Jun 12, 2026 | BUY | $50.0M |
Soni Manmeet Singh COO and CFO Jun 4, 2026 | BUY | $361.5K |
Zanganeh Mahkam Co-Chief Executive Officer Jun 4, 2026 | BUY | $1.5M |
DUGGAN ROBERT W Co-Chief Executive Officer Jun 4, 2026 | BUY | $1.5M |
Soni Manmeet Singh COO and CFO Jun 4, 2026 | BUY | $360.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
23 filings · 11 bullish · 2 bearish · 1 mixed · 9 neutral- BEARISH 8-KNov 16, 2026
Summit Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for the ivonescimab BLA, stating the application cannot be approved in its current form because the HARMONi Phase III study did not demonstrate a statistically significant overall survival benefit. The CRL is a…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 4, 2026
Summit Therapeutics filed an 8-K to register a prospectus supplement for the resale of up to…
Monitor the prospectus supplement for the conversion price and the identity of the selling stockholder to assess potential dilution and overhang. The 108.9M shares represent a significant portion of…
- NEUTRAL 8-KNov 4, 2026
Summit Therapeutics reported Q3 2026 financial results with no revenue and a GAAP net loss of…
The November 14 PDUFA date for ivonescimab in EGFR-mutated NSCLC is the primary catalyst. Approval would trigger a major revaluation; denial or a Complete Response Letter would be a significant…
- NEUTRAL INST-CLUSTERNov 4, 2026
Three asset managers doubled their SMMT positions in Q3 2026, adding $21.2M in net buying, while…
The cluster shows conviction from active managers but lacks insider corroboration and is small in scale. Monitor upcoming 13F filings for Q4 to see if these positions were maintained or reversed.
All SMMT filing & press-release reports (23)
- 8-K reportNov 16, 2026
- 8-K reportNov 4, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportNov 4, 2026
- PRESS-RELEASE reportOct 21, 2026
- DEF 14A reportOct 19, 2026
- 8-K reportSep 28, 2026
- 8-K reportSep 15, 2026
- 8-K reportSep 14, 2026
- 8-K reportSep 3, 2026
- 8-K reportAug 26, 2026
- 8-K reportAug 5, 2026
- 8-K reportJul 22, 2026
- CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- S-3ASR reportJun 9, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 4, 2026
- 8-K reportJun 3, 2026
- 8-K reportJun 1, 2026
- 8-K reportApr 30, 2026
- DEFA14A reportApr 17, 2026